11 results about "Spermatogenic Cell" patented technology

This invention discloses a Fam205a1 Methods for constructing and applying gene knockout mouse models. The construction method utilizes CRISPR / Cas9 gene editing technology, targeting mice. Fam205a1 Gene-designed specific sgRNAs for knockout Fam205a1 The regions of exons 1 through 4 of the gene are obtained. Fam205a1 Gene knockout mice. Male mice in this model exhibit infertility, specifically characterized by impaired spermatogenesis, reduced sperm motility, abnormal sperm morphology (particularly head and acrosome defects), and spermatogenic cell apoptosis. However, the weight and appearance of their testes and epididymis show no significant difference from the wild type. The mouse model constructed in this invention has stable genetic traits and a well-defined phenotype, making it an ideal animal model for studying the mechanisms of idiopathic male infertility, screening drugs for treating male infertility, or developing male contraceptives.

The invention relates to the technical field of biological medicines, and discloses an application of a plant extract composition in preparation of a medicine for improving DNA damage of testicular spermatogenic cells, and the plant extract contains a herba epimedii extract and a rhizoma polygonati extract. The invention provides new application of the composition containing the herba epimedii extract and the rhizoma polygonati extract in preparation of the medicine for improving DNA damage of the testicular spermatogenic cells, the composition can remarkably improve the DNA damage of the testicular spermatogenic cells of mice caused by cyclophosphamide, recover the multiplication capacity of the mice, inhibit apoptosis of the mice and relieve spermatogenic function damage caused by cyclophosphamide, and the composition can be used for preparing the medicine for improving the DNA damage of the testicular spermatogenic cells of the mice. And the combined administration shows a synergistic effect instead of a simple additive effect, and the drug effect is obviously superior to that of any one of the epimedium extract and the rhizoma polygonati extract which are independently administered.

The application belongs to the technical field of biology, and discloses a method for activating an ASXL2-PRC2 axis, wherein adenovirus is injected into the seminiferous tubule of an organism through an outgoing pipe to activate the expression of endogenous EZH2 and spermatocyte-specific ASXL2 in the organism. The method can be used for reducing impaired sperm motility, increasing sperm penetration and tubulin polymerization, inhibiting abnormal spermatogenesis, down-regulating the transcription level of a TZ marker, increasing the enrichment of SUZ12, EED and H3K27me3 in CEP162 and CEP290 promoters under hypoxic conditions, and slowing down hypoxia-induced abnormal spermatogenesis and spermatocyte activation of the ASXL2-PRC2 axis in the germ cell line of the organism.

The invention relates to the technical field of tumor immunotherapy, in particular to an RPL39L gene and application of a gene inhibitor of the RPL39L gene, and the RPL39L gene comprises an RPL39L gene knockout agent and small interfering RNA (Ribonucleic Acid) targeting the RPL39L gene. According to the invention, the cancer testosterone gene RPL39L is found to be ribosomeST for forming spermatogenic cell specific ribosomeST for the first time, and can regulate and control a plurality of downstream cancer testosterone genes. A gene inhibitor and small interfering RNA are designed for the RPL39L, the RPL39L is knocked out from various tumor cells such as osteosarcoma, colorectal cancer, leukemia and glioma by using a CRISPR / Cas9 technology, and the influence on the proliferation ability and migration ability of the tumor cells after the RPL39L is knocked out is proved in vitro; and shRNA of a target RPL39L coding region is designed, so that the expression level of the RPL39L in tumor cells is successfully inhibited, and the inhibition effect of the shRNA on the growth of the tumor cells is proved in vitro. The invention provides an effective means for inhibiting the expression of the cancer testosterone gene regulatory factor from the upstream, and has extremely important significance and application prospect in tumor treatment.

The invention relates to the technical field of micro-fluidic organ chips, and discloses a micro-fluidic testis organ chip and a culture method, the micro-fluidic testis organ chip comprises a PDMS fluid control layer and a PDMS cell culture layer from top to bottom; the at least three culture units are arranged on the PDMS cell culture layer in the axial direction, each culture unit internally comprises three functional areas, the three functional areas are used for testicular sertoli cell culture, spermatogenic cell culture and basement membrane simulation respectively, and the three functional areas are communicated with one another to form a fluid path; the regulation and control part is arranged on the PDMS fluid control layer, and the regulation and control part is used for regulating and controlling fluid paths which are communicated with one another among the three functional areas; the inoculation and collection part is arranged on the PDMS fluid control layer and is used for carrying out cell inoculation and collection in the three functional areas. The in-vivo testis spermatogenesis microenvironment is highly simulated, the limitation of a traditional 2D cell experiment and an animal experiment can be effectively made up, and a new method and platform are provided for analyzing a spermatogenesis disorder mechanism and screening targeted repair drugs.

The invention relates to the field of microbial fermentation, and particularly discloses a fermentation method and a fermentation device of a polygonatum sibiricum and cistanche deserticola fermentation product. Comprising a shell, a mounting cavity and a culture cavity are formed in the shell, and a sealing door is mounted on the front side of the culture cavity; the placement mechanism comprises a supporting plate arranged in the culture cavity, a culture box is placed at the upper end of the supporting plate, a rectangular insertion block is fixedly connected to the upper end of the supporting plate, a rectangular insertion groove matched with the rectangular insertion block is formed in the lower end of the culture box, and an annular flow dividing cavity is formed in the culture box; the annular flow dividing cavity is communicated with the inner bottom of the culture box through a plurality of flow dividing holes; and a gas circulation movement mechanism. According to the fermentation method, lactobacillus rhamnosus is adopted to ferment the rhizoma polygonati and cistanche extracting solution, the number and quality of spermatogenic cells are improved, the fermentation device is matched with nitrogen bubble supply, movement of fermentation liquor is promoted, the uniformity of fermentation temperature and fermentation quality is guaranteed, and therefore the fermentation efficiency is guaranteed.

The invention relates to the technical field of medical detection, in particular to an antibody combination for detecting spermatogenic cells, a kit and application of the antibody combination. The antibody combination comprises an antibody of a zinc finger transcription factor 4, an antibody of a conjugation complex protein 3 and an antibody of zona pellucida binding protein. Specific recognition and semi-quantitative analysis of spermatogenic cells of all levels in samples are realized through standardized pretreatment, full-automatic immunohistochemical staining and digital image analysis for different types of samples; the method breaks through the technical bottlenecks that the traditional HE staining or Wright-Giemsa staining method is strong in subjectivity, difficult to distinguish cells with similar forms and greatly influenced by cell states and staining effects, and provides an efficient detection means for accurate pathological typing, spermatogenic function evaluation and dynamic curative effect monitoring of male infertility.

Provided is use of PGAM2 in the breeding of Blcattle black cattle, which belongs to the technical field of molecular biological breeding, in which individuals having a high PGAM2 content are screened as high-quality breeding bulls. In the present disclosure, it is proved by means of experiments that PGAM2 may promote the proliferation and glycolytic metabolism of Sertoli cells to produce lactic acid, an energy substrate required for spermatogenic cell development. It regulates the formation of blood-testis barrier and facilitates the communication between Sertoli cells and germ cells, thereby promoting spermatogenesis. The present disclosure provides a new direction for the breeding of Blcattle black cattle for high quality beef production.

The invention belongs to the technical field of biological medicines, and particularly relates to application of fumaric acid in preparation of a product for preventing, improving or treating male dyszoospermia. In a specific embodiment, the invention relates to application of fumaric acid in preparation of a product for preventing, improving or treating senile male dyszoospermia. In experiments, the inventor finds that fumaric acid can obviously improve the sperm concentration of old mice, improve the number of spermatogenic cells and improve the serum testosterone level of the old mice. The fumaric acid is used for treating the male reproductive dysfunction of the elderly for the first time, an ideal treatment effect is achieved, a new choice is provided for clinically treating the male reproductive dysfunction of the elderly, and the fumaric acid has extremely high application value and social benefits.

The application discloses application of a natural product composition in preparation of medicines for preventing or treating azoospermia. The natural product composition is composed of astragalin and curcumin. The natural product composition composed of astragalin and curcumin can inhibit spermatogenic cell apoptosis by synergistically regulating Nrf2 / HO-1 / HIF-1a, and improve rat azoospermia. Compared with western medicines, the natural product composition has a wider treatment window and smaller toxic side effect, and has application prospects in the medicines for preventing or treating azoospermia.

The invention discloses an application of L-phenylalanyl-L-lysine in improving a spermatogenic function. The L-phenylalanyl-L-lysine is proposed for the first time to be capable of remarkably increasing sperm concentration, improving sperm malformation, improving sperm motility and effectively improving the spermatogenic function. Meanwhile, L-phenylalanyl-L-lysine is used for treating oligoasthenozoospermia, can promote thickening of spermatogenic tubule spermatogenic cell layers, increase spermatogenic cell areas, improve sperm differentiation and formation processes, relieve spermatogenic dysfunction of testicular tissues and increase the total number of sperms, is remarkable in treatment effect and high in safety, and has excellent clinical transformation prospects.